Nivolumab Induced Autoimmune Like Gastritis: A case report |Biomedgrid

Immune checkpoint inhibitors (ICPI) such as ipilimumab (anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody) and nivolumab (antiprogrammed cell death protein-1 (PD-1) antibodies) are novel chemotherapeutic agents used in multiple advanced metastatic malignancies. They are well known for their immune-related adverse events [1]. Although diarrhea and enterocolitis have been documented as gastrointestinal side effects of ICPI, gastritis has been rarely reported as a side effect of ICPI. Here, we present a case of a 65-years old female with advanced hepatocellular carcinoma who developed autoimmune like gastritis after treatment with Nivolumab [2].